Emergent Biosolutions Inc. (EBS) vs Evolus, Inc. (EOLS)
- Emergent Biosolutions Inc. EBS 6.38 −11.14%
- Evolus, Inc. EOLS 7.10 −6.21%
Emergent Biosolutions Inc. and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Evolus, Inc. is the larger, with a market value of $500.0M against $368.1M — 1.4× the size. Evolus, Inc. grew revenue faster over the last twelve months: 13.9% against −9.56%. Evolus, Inc. has the higher net margin (−10.9% vs −23.0%) and the lower return on invested capital (−14.5% vs −5.27%). Across the 18 metrics below, Evolus, Inc. leads on 10 and Emergent Biosolutions Inc. on 8.
Valuation
Profitability
| Metric | EBS | EOLS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 55.87% | 66.74% | 53.94% |
| Operating margin | (8.57%) | (5.90%) | 0.00% |
| Net margin | (22.96%) | (10.85%) | 0.00% |
| Free cash flow margin | 11.18% | (6.92%) | 0.00% |
| Return on equity | (40.29%) | 138.57% | (0.40%) |
| Return on assets | (13.95%) | (14.40%) | (3.32%) |
| Return on invested capital | (5.27%) | (14.47%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack